Aptamer Sciences Past Earnings Performance
Past criteria checks 0/6
Aptamer Sciences's earnings have been declining at an average annual rate of -36.6%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 0.09% per year.
Key information
-36.6%
Earnings growth rate
-2.6%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 0.09% |
| Return on equity | -103.7% |
| Net Margin | -6,237.6% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Aptamer Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 216 | -13,477 | 2,851 | 8,944 |
| 31 Dec 23 | 243 | -13,602 | 2,746 | 9,359 |
| 30 Sep 23 | 284 | -13,668 | 2,704 | 11,472 |
| 30 Jun 23 | 321 | -10,785 | 2,661 | 8,867 |
| 31 Mar 23 | 377 | -8,588 | 2,359 | 7,396 |
| 31 Dec 22 | 358 | -7,116 | 2,289 | 6,025 |
| 30 Sep 22 | 293 | -5,785 | 2,227 | 3,687 |
| 30 Jun 22 | 278 | -5,416 | 2,086 | 3,362 |
| 31 Mar 22 | 263 | -3,978 | 2,212 | 1,730 |
| 31 Dec 21 | 269 | -3,831 | 2,024 | 1,763 |
| 30 Sep 21 | 267 | -3,597 | 1,779 | 1,794 |
| 30 Jun 21 | 284 | -3,728 | 1,910 | 1,814 |
| 31 Mar 21 | 268 | -3,703 | 1,918 | 1,769 |
| 31 Dec 20 | 229 | -3,843 | 1,988 | 1,770 |
| 30 Sep 20 | 246 | -3,829 | 2,003 | 1,693 |
| 30 Jun 20 | 335 | -3,941 | 1,919 | 1,848 |
| 31 Mar 20 | 356 | -4,921 | 1,910 | 1,575 |
| 31 Dec 19 | 408 | -3,853 | 1,913 | 1,446 |
| 31 Dec 18 | 276 | -7,345 | 1,972 | 1,439 |
| 31 Dec 17 | 167 | -5,959 | 1,130 | 1,053 |
| 31 Dec 16 | 125 | -1,371 | 824 | 477 |
Quality Earnings: A291650 is currently unprofitable.
Growing Profit Margin: A291650 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A291650 is unprofitable, and losses have increased over the past 5 years at a rate of 36.6% per year.
Accelerating Growth: Unable to compare A291650's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A291650 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.1%).
Return on Equity
High ROE: A291650 has a negative Return on Equity (-103.73%), as it is currently unprofitable.